Granite Harbor Advisors Inc. Raises Position in Pfizer Inc. $PFE

Granite Harbor Advisors Inc. increased its holdings in Pfizer Inc. (NYSE:PFE) by 41.3% during the second quarter, HoldingsChannel reports. The institutional investor owned 13,748 shares of the biopharmaceutical company’s stock after acquiring an additional 4,020 shares during the quarter. Granite Harbor Advisors Inc.’s holdings in Pfizer were worth $333,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the first quarter worth $27,000. North Capital Inc. bought a new position in Pfizer in the first quarter valued at $28,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer in the second quarter valued at $29,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer in the first quarter valued at $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.72 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17. The firm has a market cap of $140.52 billion, a P/E ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. The company has a 50 day moving average of $24.88 and a 200 day moving average of $24.13.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s payout ratio is 91.49%.

Wall Street Analyst Weigh In

PFE has been the topic of a number of research analyst reports. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group reiterated a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Finally, Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.